| Windrose Health Network - Trafalgar | |
|
14 Trafalgar Sq Trafalgar IN 46181-9515 | |
| (317) 412-9190 | |
| (317) 878-2302 |
| Full Name | Windrose Health Network - Trafalgar |
|---|---|
| Speciality | Clinic/Center |
| Location | 14 Trafalgar Sq, Trafalgar, Indiana |
| Authorized Official Name and Position | Michael K Kolenda (CEO) |
| Authorized Official Contact | 3177394895 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Windrose Health Network - Trafalgar 14 Trafalgar Sq Trafalgar IN 46181-9515 Ph: (317) 412-9190 | Windrose Health Network - Trafalgar 14 Trafalgar Sq Trafalgar IN 46181-9515 Ph: (317) 412-9190 |
| NPI Number | 1255611331 |
|---|---|
| Provider Enumeration Date | 08/22/2011 |
| Last Update Date | 10/09/2019 |
| Medicare PECOS PAC ID | 8426965039 |
|---|---|
| Medicare Enrollment ID | O20040210001139 |
News Archive
In recent decades much hope was based on the development of personalised drug treatments, in which genetic tests determine the choice and optimal dose of medication for each individual patient. However, the real breakthrough is still to be seen, and now researchers at Karolinska Institutet show in two separate scientific papers that many more gene variants affect how a person responds to medication than previously thought - and thus that today's analytical tools are too coarse.
The factors instrumental in triggering latent tuberculosis infection to progress into active disease have long remained elusive to researchers. New insight into the mystery is provided by Professor David Russell, speaking at the Society for General Microbiology's spring meeting in Edinburgh today. His work could help develop innovative strategies for treating the disease.
The National Science Foundation/U.S. News & World Report ask the question: "Airlines protect themselves from passenger 'no-shows' by overbooking. Could the same approach—overbooking patients—work in a doctor's office or hospital?" As part of a study examining such a question, the Center for Health Organization Transformation is looking at projects around the nation where "systems engineering" — the implementation of systems used in other industries — can reduce health care costs.
Repros Therapeutics today announced financial results for the first quarter ended March 31, 2010.
Bristol-Myers Squibb Company announced today that belatacept, an investigational selective T cell co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of eight clinical presentations related to kidney transplantation at the American Transplant Congress, being held May 1 - 5 in San Diego.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255611331 | NPI | - | NPPES |
| 200127470A | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QF0400X | Clinic/center - Federally Qualified Health Center (fqhc) | (* (Not Available)) | Primary |
News Archive
In recent decades much hope was based on the development of personalised drug treatments, in which genetic tests determine the choice and optimal dose of medication for each individual patient. However, the real breakthrough is still to be seen, and now researchers at Karolinska Institutet show in two separate scientific papers that many more gene variants affect how a person responds to medication than previously thought - and thus that today's analytical tools are too coarse.
The factors instrumental in triggering latent tuberculosis infection to progress into active disease have long remained elusive to researchers. New insight into the mystery is provided by Professor David Russell, speaking at the Society for General Microbiology's spring meeting in Edinburgh today. His work could help develop innovative strategies for treating the disease.
The National Science Foundation/U.S. News & World Report ask the question: "Airlines protect themselves from passenger 'no-shows' by overbooking. Could the same approach—overbooking patients—work in a doctor's office or hospital?" As part of a study examining such a question, the Center for Health Organization Transformation is looking at projects around the nation where "systems engineering" — the implementation of systems used in other industries — can reduce health care costs.
Repros Therapeutics today announced financial results for the first quarter ended March 31, 2010.
Bristol-Myers Squibb Company announced today that belatacept, an investigational selective T cell co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of eight clinical presentations related to kidney transplantation at the American Transplant Congress, being held May 1 - 5 in San Diego.
› Verified 7 days ago
Edinburgh/trafalgar Family Health Centers, Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 14 Trafalgar Sq, Trafalgar, IN 46181 Phone: 317-878-2301 Fax: 317-878-2302 | |
Windrose Health Network, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 14 Trafalgar Sq, Trafalgar, IN 46181 Phone: 317-739-4895 |